News
Stay updated with the latest innovations and news from Quantoom Biosciences!
Rio de Janeiro, Brazil – November 29, 2024 – During the Belgian Economic Mission to Brazil, a historic Memorandum of…
ST Pharm, a leading technology-driven RNA CDMO, and Quantoom Biosciences (also referred as “Quantoom”), a specialized RNA technology platform developer,…
DURHAM, North Carolina – Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A., focused on mRNA production technologies for vaccines and…
Nivelles, Belgium – Quantoom Biosciences S.A. (“Quantoom”), a subsidiary of Univercells S.A., proudly announces the extension of the Ntensify™ product…
Quantoom Biosciences S.A. (“Quantoom”), part of Univercells S.A. is proud to announce its significant collaboration with the Institute of Technology…
The Ntensify™ Midi System Sets the Stage for Equitable Vaccine Access Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, proudly announces…
Quantoom Biosciences (‘Quantoom’) is thrilled to announce a new collaboration with Stevanato Group, a leading global provider of drug containment and…
Quantoom Biosciences S.A. (“Quantoom”), a Univercells company, is proud to unveil the latest addition to its offering: a service for…
Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented…
Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through…
Univercells S.A. introduces its latest affiliate, Quantoom Biosciences S.A., a biotech with the mission to improve access to essential medicines…
